Biota Holdings Ltd.  

(Public, ASX:BTA)   Watch this stock  
Find more results for BTA
0.0000
- Close
ASX data delayed by 20 mins - Disclaimer
Currency in
Range     -
52 week 0.57 - 1.07
Open     -
Vol / Avg. 0.00/217,845.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -0.10
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '12) 2012
Net profit margin -81.48% -84.28%
Operating margin -82.13% -86.66%
EBITD margin - -73.29%
Return on average assets -34.64% -24.81%
Return on average equity -38.80% -27.83%
Employees 34 -
CDP Score - -

Address

Unit 10 585 Blackburn Road, NOTTING HILL
MELBOURNE, VIC 3168
Australia
+61-3-99153700 (Phone)
+61-3-99153702 (Fax)

Website links

Description

Biota Holdings Limited is engaged in the drug discovery and clinical development of anti-infectives, suitable for human use and commercialization. The Company licensed zanamivir, which is a neuraminidase inhibitor (influenza antiviral), to GlaxoSmithKline (GSK) and marketed as Relenza. The Company�s research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. The Company has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems. In addition, the Company and Daiichi Sankyo co-own a range of second generation influenza antivirals, of which the lead product lnavir, is approved for marketing in Japan.

Officers and directors

Peter Chapman Cook Chief Executive Officer, Managing Director, Executive Director
Damian T. Lismore Chief Financial Officer, Company Secretary
Vivienne Green Vice President-Human Resources
Jane Ryan Ph.D. Vice President of Product Development and Strategic Marketing
Simon Tucker Ph.D. Vice President of Research
Leigh Farrell Vice President - Business Development
John Lambert Ph.D. Principal Director of Product Development Operations
James Charles Fox Ph.D. Non-Executive Chairman of the Board
Age: 62
Paul R. Bell Non-Executive Independent Director
Ian D. Gust Non-Executive Independent Director